David M. Smadja, Qun-Ying Yue, Richard Chocron, Olivier Sanchez, Agnes Lillo-Le Louet.
COVID-19 is associated with a prothrombotic phenotype characterized by coagulopathy and endothelial dysfunction (1-4). Following some cases of thrombosis after vaccination, OxfordAstraZeneca vaccine (AZD1222) was temporarily suspended by some European countries. The European medicines agency (EMA) concluded that the benefits of the vaccine in combating COVID-19 outbreak continue to outweigh the risk of side effects. On March 19, 2021, Germany reported 13 cases of sinus or cerebral vein thrombosis with more than 1.6 million AstraZeneca COVID-19 vaccine doses administered. Some of these patients also had a heparin-induced thrombocytopenia (HIT)-like syndrome, which does suggest an immunological event as one of the potential origin of thrombosis
Read the Editorial « European Respiratory journal » :